# Enanta Pharmaceuticals, Inc clinical trials: 46 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 46 trials with Enanta Pharmaceuticals, Inc as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Enanta Pharmaceuticals, Inc: 46 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/enanta-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 46
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 46, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07908381 | A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe... | Enanta Pharmaceuticals, Inc | Phase 2/3 | Recruiting | RSV | 860 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908381) |
| April 21, 2026 | NCT07540910 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy... | Enanta Pharmaceuticals, Inc | Phase 1 | Recruiting | Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07540910) |
| March 19, 2026 | NCT07482657 | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With... | Enanta Pharmaceuticals, Inc | Phase 2 | Recruiting | RSV Infection, RSV, Respiratory Syncytial Virus (RSV) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07482657) |
| April 8, 2025 | NCT06917508 | A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | RSV Infection, Drug Drug Interaction | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06917508) |
| February 26, 2025 | NCT06847464 | A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and... | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | RSV Infection, Drug Drug Interaction (DDI) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06847464) |
| September 19, 2024 | NCT06601192 | A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | RSV Infection, QTc Interval | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06601192) |
| December 14, 2023 | NCT06170242 | A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model | Enanta Pharmaceuticals, Inc | Phase 2 | Completed | RSV Infection | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06170242) |
| November 15, 2022 | NCT05616728 | A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 | Enanta Pharmaceuticals, Inc | Phase 2 | Completed | COVID-19 | 231 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05616728) |
| October 26, 2022 | NCT05594615 | Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | COVID-19 | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05594615) |
| October 26, 2022 | NCT05594602 | Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects. | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | COVID-19 | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05594602) |
| October 20, 2022 | NCT05587478 | A Study of EDP-323 in Healthy Subjects | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | RSV Infection | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05587478) |
| October 6, 2022 | NCT05568706 | A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. | Enanta Pharmaceuticals, Inc | Phase 2 | Completed | RSV Infection | 187 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05568706) |
| February 18, 2022 | NCT05246878 | A Study of EDP-235 in Healthy Subjects | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | SARS CoV 2 Infection | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05246878) |
| July 21, 2021 | NCT04971512 | A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS... | Enanta Pharmaceuticals, Inc | Phase 1 | Terminated | Chronic Hepatitis B Virus Infection | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04971512) |
| June 16, 2021 | NCT04927793 | Absorption, Metabolism, and Excretion (AME) Study of \[14C\]EDP-938 in Healthy Male Subjects | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | Respiratory Syncytial Virus (RSV) | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04927793) |
| May 4, 2021 | NCT04871724 | Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | RSV Infection | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04871724) |
| March 25, 2021 | NCT04816721 | A Study to Evaluate EDP 938 Regimens in Children With RSV | Enanta Pharmaceuticals, Inc | Phase 2 | Completed | Respiratory Syncytial Virus (RSV) | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04816721) |
| March 5, 2021 | NCT04783753 | Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | Hepatitis B | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04783753) |
| November 18, 2020 | NCT04633187 | Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract | Enanta Pharmaceuticals, Inc | Phase 2 | Terminated | Respiratory Syncytial Virus Infections | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04633187) |
| September 22, 2020 | NCT04559126 | A Study of EDP-297 in Healthy Subjects | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04559126) |
| August 4, 2020 | NCT04498741 | Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | RSV Infection | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04498741) |
| July 14, 2020 | NCT04470388 | A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | Chronic HBV Infection | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04470388) |
| May 7, 2020 | NCT04378010 | A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH | Enanta Pharmaceuticals, Inc | Phase 2 | Terminated | Non-Alcoholic Steatohepatitis | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04378010) |
| December 12, 2019 | NCT04196101 | A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects | Enanta Pharmaceuticals, Inc | Phase 2 | Completed | Respiratory Syncytial Virus | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04196101) |
| July 5, 2019 | NCT04008004 | A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2) | Enanta Pharmaceuticals, Inc | Phase 1 | Completed | Chronic HBV Infection | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04008004) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 33 |
| Phase 2 | 12 |
| Phase 2/3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 38 |
| Terminated | 4 |
| Recruiting | 3 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Respiratory Syncytial Virus Infections | 14 |
| Non-alcoholic Fatty Liver Disease | 6 |
| Hepatitis B | 4 |
| COVID-19 | 4 |
| Hepatitis C | 3 |
| Liver Cirrhosis, Biliary | 1 |
| Hepatitis B, Chronic | 1 |
| Chronic Inducible Urticaria | 1 |
| Chronic Urticaria | 1 |
| Soft Tissue Infections | 1 |
| Community-Acquired Pneumonia | 1 |
| Infections | 1 |
| Communicable Diseases | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Fatty Liver | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [E-commerce services in the United States](https://specstream.ai/data/businesses/e-commerce-services/united-states)
- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
- [Hotels in the United States](https://specstream.ai/data/businesses/hotels/united-states)
- [Lighting fixture manufacturers in the United States](https://specstream.ai/data/businesses/lighting-fixture-manufacturers/united-states)
- [Occupational therapy clinics in the United States](https://specstream.ai/data/businesses/occupational-therapy-clinics/united-states)
